CN117715612A - 包括掺杂硅颗粒的组合物以及相关方法 - Google Patents

包括掺杂硅颗粒的组合物以及相关方法 Download PDF

Info

Publication number
CN117715612A
CN117715612A CN202280051843.7A CN202280051843A CN117715612A CN 117715612 A CN117715612 A CN 117715612A CN 202280051843 A CN202280051843 A CN 202280051843A CN 117715612 A CN117715612 A CN 117715612A
Authority
CN
China
Prior art keywords
pharmaceutical composition
particles
doped silicon
nucleic acid
lipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280051843.7A
Other languages
English (en)
Chinese (zh)
Inventor
R·S·萨菲-西伯特
M·艾哈迈德
F·苏特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sisaf Ltd
Original Assignee
Sisaf Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sisaf Ltd filed Critical Sisaf Ltd
Publication of CN117715612A publication Critical patent/CN117715612A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280051843.7A 2021-07-23 2022-07-22 包括掺杂硅颗粒的组合物以及相关方法 Pending CN117715612A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110644.8A GB202110644D0 (en) 2021-07-23 2021-07-23 Improved nucleic acid vector particles
GB2110644.8 2021-07-23
PCT/GB2022/051937 WO2023002222A1 (en) 2021-07-23 2022-07-22 Compositions comprising doped silicon particles, and related methods

Publications (1)

Publication Number Publication Date
CN117715612A true CN117715612A (zh) 2024-03-15

Family

ID=77541197

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280051843.7A Pending CN117715612A (zh) 2021-07-23 2022-07-22 包括掺杂硅颗粒的组合物以及相关方法

Country Status (7)

Country Link
US (1) US20240327841A1 (https=)
EP (1) EP4351510A1 (https=)
JP (1) JP2024527441A (https=)
CN (1) CN117715612A (https=)
AU (1) AU2022315872A1 (https=)
GB (1) GB202110644D0 (https=)
WO (1) WO2023002222A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202300914D0 (en) 2023-01-20 2023-03-08 Sisaf Ltd Manufacturing process
GB202300915D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd mRNA COMPOSITIONS
GB202300912D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compostions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO2009046220A2 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
IT1394656B1 (it) 2009-07-03 2012-07-05 Brev Angela Srl Processo per la produzione e l'assemblaggio di una siringa per operazioni medicali
GB0913255D0 (en) * 2009-07-30 2009-09-02 Sisaf Ltd Topical composition
NZ606591A (en) * 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2017181115A1 (en) * 2016-04-14 2017-10-19 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
CN112494424A (zh) * 2020-12-04 2021-03-16 合肥澄实生物科技有限公司 一种脂质纳米颗粒制剂及其应用

Also Published As

Publication number Publication date
WO2023002222A1 (en) 2023-01-26
JP2024527441A (ja) 2024-07-24
EP4351510A1 (en) 2024-04-17
US20240327841A1 (en) 2024-10-03
GB202110644D0 (en) 2021-09-08
AU2022315872A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US20240327841A1 (en) Compositions comprising doped silicon particles, and related methods
US20240327870A1 (en) Nucleic acid vector compositions
EP2687204B1 (en) Vector for pulmonary delivery, inducing agent, and uses
JP2022529579A (ja) ケイ素ナノ粒子を含む送達システム
EP3706716A1 (en) Improved lipid-peptide nanocomplex formulation for mrna delivery to cells
EP4311559A1 (en) Nanoparticles and peptides for the delivery of cargos to chondrocytes
Li et al. A novel cationic liposome formulation for efficient gene delivery via a pulmonary route
JP2025525497A (ja) 脂質製剤
EP2910564B1 (en) Weakly acidic ph-responsive peptide and liposome containing same
US12594239B2 (en) Protection of biological species from degradation
CN117460537A (zh) 核酸递送
CN120603580A (zh) 治疗组合物和方法
JP6404034B2 (ja) 核酸を内封してなる中性又はアニオン性リポソーム及びその製造方法。
EP4124345A1 (en) Nanoparticles for muscle delivery
EP4651856A1 (en) Therapeutic compositions and methods
WO2024153953A1 (en) mRNA COMPOSITIONS
WO2025166259A1 (en) Mineral binding mrna lipid nanoparticles
WO2022230485A1 (ja) 経肺又は経鼻投与用ワクチン組成物
CN116997326A (zh) 开发基因组编辑球形核酸（sna）的策略
EP4651858A1 (en) Manufacturing process for hybrid lipid particles
Jafari et al. Serum Stability and Physicochemical Characterization of a Novel Amphipathic Peptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination